Thermo Fisher Scientific has launched the Oncomine Childhood Cancer Research Assay, a next-generation sequencing panel developed in collaboration with Children’s Hospital Los Angeles.
Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.
To fully benefit from the vast quantities of data from TCGA, tools for easy data visualisation and analysis must be developed for use of the non-computational scientist. Our panel of experts discuss TCGA data and the tools needed to make sense of it.
New data indicates that newly diagnosed lung cancer patients have a 50% increase in survival rate over 1 year when receiving Keytruda over traditional chemotherapy.
Researchers around the globe can now access thousands of paediatric cancer genomic datasets, thanks to a new cloud-based initiative.
Researchers have uncovered a new protein shield that aids in repairing damaged DNA in cells and affects resistance to drugs doctors use to treat breast cancer.
Researchers have determined how satellite DNA, considered to be “junk DNA”, plays a crucial role in holding the genome together.
Hidden layers of regulation that control the activity of genes can produce drug-resistant, surviving cells. New research helps explain how therapy-resistant cancers arise — findings with important implications for the future of cancer therapy.
GlaxoSmithKline Chief Executive, Emma Wamsley is keeping her promise to cut the drugmaker’s pharmaceutical portfolio — the company said today that it is handing its rare disease gene therapy drugs to Orchard Therapeutics.
A new cancer cell-based assay could help doctors diagnose cancer, better monitor the disease, and take a step closer to customised treatment for individual patients.
A literature review finds an increased risk of cancer, late-stage cancer, and mortality, with increased waiting time between a positive screening and start of diagnostic testing.
Use of one of a cancer treatment offered on the basis of biomarkers instead of tissue type is being restricted because of inaccurate, insensitive diagnostic tests.
Material left out of common processes for sequencing genetic material in cancer tumours may actually carry important information about why only some people respond to immunotherapy.
Scientists have developed a straightforward, computational way to measure cellular age, a feat that may lead to better, simpler screening and monitoring methods for cancer and other diseases.
Researchers have identified nearly 200 mutations in non-coding DNA that play a role in cancer. Each mutation could represent a new cancer drug target.